Ultragenyx Pharmaceutical Inc at Stifel Healthcare Conference Transcript
All right. Good afternoon, everyone. Thanks for joining the afternoon session. My name is Dave Ona. I'm one of the biotech analysts here. With me for this next 25, 30 minutes, we have Ultragenyx. And with me on stage, we have Founder President and CEO, Emil Kakkis. Dr. Emil Kakkis, we'll start off with a short intro of the company, a couple of slides accompanying it, and then we'll jump right into the question.Â
So with that, Emil, thank you.
Thanks for having me, Dave. I'm good to be here. So our forward-looking statement. As a company, we were formed in 2010. So this is completed 12 years. We're in the 2013, '14 IPO class. And we have a growing commercial revenue, we talk about now with 3 products, the fourth product we just acquired with high growth. Plus, we also have a strong clinical pipeline with 5 programs at Pivotal or post pivotal and combine that, we have not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
